|
|
Article: Inotek Nabs $19.3M Series C For PARP And Other Programs.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
With its lead product partnered to Genentech Inc., Inotek Pharmaceuticals Corp. raised $19.3 million in a Series C financing to support clinical trials with the next few compounds in its pipeline.
New investors in the round included Hercules Technology Growth Capital Inc., Meditor Capital Management and Mitsubishi UFJ Capital. Inotek's Chief Business Officer Jeffrey Walsh noted that while Hercules is well known for providing venture debt, in this case, the firm made an equity investment.
All of Inotek's existing investors also participated in the insider-led round, including Care Capital LLC, La Caisse de depôt et placement ...